IQVIA Holdings Inc. $IQV Holdings Lowered by Schwartz Investment Counsel Inc.

by · The Cerbat Gem

Schwartz Investment Counsel Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 42.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,000 shares of the medical research company’s stock after selling 46,290 shares during the period. Schwartz Investment Counsel Inc.’s holdings in IQVIA were worth $12,156,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Alliancebernstein L.P. boosted its stake in IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA in the second quarter valued at $515,772,000. JPMorgan Chase & Co. boosted its stake in IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares in the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after acquiring an additional 253,759 shares during the period. Finally, Lazard Asset Management LLC raised its position in IQVIA by 6.1% in the second quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after acquiring an additional 107,500 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. Stifel Nicolaus lifted their price objective on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Barclays set a $230.00 price target on shares of IQVIA in a research report on Monday, December 15th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Finally, Evercore ISI upped their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.19.

Read Our Latest Stock Analysis on IQV

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV opened at $238.03 on Monday. The firm has a market capitalization of $40.54 billion, a P/E ratio of 32.65, a PEG ratio of 2.42 and a beta of 1.36. The stock has a fifty day moving average of $227.30 and a 200-day moving average of $203.61. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Further Reading